The prostate cancer specific piece was part of a larger study including breast, colorectal, lung, and ovarian cancer. Overall, 67 groups from around the world provided 105,000 samples for the prostate cancer analysis. Professor Eeles presented preliminary results of 98,500 European samples, approximately 20% of which comprised aggressive cases. She cautioned that the generalizability of these results may not apply to minority groups.
The SNP profile defined by the OncoArray chip gives a polygenic risk score which can be stratified into percentiles. The highest 1% risk category was associated with a 5.72 (95% CI 5.04-6.49) relative risk of having prostate cancer over the course of a man’s lifetime compared to the 25-75% risk category. Conversely, the lowest 1% risk category had a relative risk of 0.17 (95% CI 0.13-0.23). These data are currently being incorporated into counseling patients with a family history of prostate cancer as a risk stratification tool in the UK.
Presented By: Rosalind Eeles
Written By: Benjamin T. Ristau, MD, Society of Urologic Oncology Fellow, Fox Chase Cancer Center
at the 2017 Genitourinary Cancers Symposium - February 16 - 18, 2017 – Orlando, Florida USA
The SNP profile defined by the OncoArray chip gives a polygenic risk score which can be stratified into percentiles. The highest 1% risk category was associated with a 5.72 (95% CI 5.04-6.49) relative risk of having prostate cancer over the course of a man’s lifetime compared to the 25-75% risk category. Conversely, the lowest 1% risk category had a relative risk of 0.17 (95% CI 0.13-0.23). These data are currently being incorporated into counseling patients with a family history of prostate cancer as a risk stratification tool in the UK.
Presented By: Rosalind Eeles
Written By: Benjamin T. Ristau, MD, Society of Urologic Oncology Fellow, Fox Chase Cancer Center
at the 2017 Genitourinary Cancers Symposium - February 16 - 18, 2017 – Orlando, Florida USA